Upendra Mahat, Asha Das, Vijay Kumar, Vinay Prasad
This Viewpoint discusses the recent decision by the US Food and Drug Administration to eliminate Risk Evaluation and Mitigation Strategies requirements for chimeric antigen receptor (CAR) T-cell therapies for the treatment of cancer.